A kidney transplant recipient has no sulfonamide allergy and is at risk for cytomegalovirus infection. Which prophylaxis plan should the nurse expect during early follow-up?
1Prescribed trimethoprim-sulfamethoxazole for PCP and valganciclovir for CMV prevention.✓ Correct answer
2Daily ciprofloxacin for PCP and acyclovir as the standard CMV prevention regimen.
3Oral nystatin for CMV and rifampin as the standard PCP prevention regimen.
4Live-virus vaccination during peak immunosuppression instead of antimicrobial prophylaxis.
Explanation
Kidney transplant recipients routinely receive trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia prophylaxis, and recipients at CMV risk receive oral ganciclovir or valganciclovir according to donor-recipient serology and the transplant protocol. Nystatin or clotrimazole can be used for Candida prophylaxis but does not prevent CMV. Ciprofloxacin and rifampin are not standard PCP prophylaxis, and live vaccines are not substituted for prescribed antimicrobial prevention during immunosuppression.
Clinical reasoning Immunosuppression creates predictable opportunistic-infection windows. TMP-SMX covers PCP and also reduces early urinary infection risk, while valganciclovir targets CMV risk determined by transplant serology and therapy.
Decision rule Verify the organ-specific prophylaxis plan, renal-adjusted doses, blood counts, kidney function, and adherence rather than substituting unrelated antimicrobials or live vaccines.
Scenario 40-year-old female 1 week post-kidney transplant; pre-discharge med reconciliation.
Pneumocystis prophylaxis — Preventive therapy with trimethoprim-sulfamethoxazole used after kidney transplantation to reduce PCP risk.
CMV prophylaxis — Risk-directed antiviral prevention with ganciclovir or valganciclovir after transplantation.
Live vaccine contraindication — Live vaccines (MMR, varicella, yellow fever, live flu, oral polio) contraindicated in immunosuppression.